Single Dose of Albendazole in the Treatment of Cutaneous Larva Migrans
Angel R. Orihuela
Abstract
Angel R. Orihuela
Abstract
To the Editor.— The syndrome of cutaneous larva migrans, also known as creeping eruption, is a process commonly found in inhabitants of tropical or subtropical regions of the world. It is caused by penetration of the skin by infective larvae of hookworms from various animals.Ancylostoma braziliense, a hookworm of cats and dogs, causes most cases, although other nematodes, includingAncylostoma caninum, Uncinaria stenocephala, andBunostomum phlebotomusare occasional causes.1 Thiabendazole, 25 mg/kg per day orally, for two consecutive days, is currently considered the drug of choice. Alternatively, topical application of an aqueous 10% suspension of the compound (500 mg per 5 ml), has been advocated as equally effective, and essentially devoid of toxic side effects.2 As thiabendazole has become unavailable in many countries, and since other suggested alternatives, such as oral or topical mebendazole, have not lived up to early expectations, any addition to the therapeutic armamentarium
OpenAlex reports 32 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
To the Editor.— The syndrome of cutaneous larva migrans, also known as creeping eruption, is a process commonly found in inhabitants of tropical or subtropical regions of the world. It is caused by penetration of the skin by infective larvae of hookworms from various animals.Ancylostoma braziliense, a hookworm of cats and dogs, causes most cases, although other nematodes, includingAncylostoma caninum, Uncinaria stenocephala, andBunostomum phlebotomusare occasional causes.1 Thiabendazole, 25 mg/kg per day orally, for two consecutive days, is currently considered the drug of choice. Alternatively, topical application of an aqueous 10% suspension of the compound (500 mg per 5 ml), has been advocated as equally effective, and essentially devoid of toxic side effects.2 As thiabendazole has become unavailable in many countries, and since other suggested alternatives, such as oral or topical mebendazole, have not lived up to early expectations, any addition to the therapeutic armamentarium
Key concepts: Cutaneous larva migrans, Ancylostoma caninum, Albendazole, Mebendazole, Medicine, Larva, Veterinary medicine, Anthelmintic